These results were obtained from the 32-week prospective, observational cohort REVEAL study among eligible individuals with the rare, chronic blood disorder who wore a digital wearable ...

Please provide your email address to receive an email when new articles are posted on . Researchers reviewed the efficacy of ravulizumab based on 2-year data from two phase 3, single-arm studies. eGFR ...

– ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) – “ULTOMIRIS has already provided patients with greater flexibility ...

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending ...

STOCKHOLM, Sweden — A new drug under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), ravulizumab (ALXN1210, Alexion Pharmaceuticals), has shown noninferiority compared with ...

Please provide your email address to receive an email when new articles are posted on . Ravulizumab led to maintained control of intravascular hemolysis and sustained stable hemoglobin levels ...

BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...

BARCELONA, Spain — Use of ravulizumab for long-term treatment of neuromyelitis optica spectrum disorder (NMOSD) offered sustained protection from relapse for at least 3 years, results from the ...

A recent study found that a composite end point developed by the researchers gave a single and simultaneous measurement of the overall benefit of treatment for paroxysmal nocturnal hemoglobinuria (PNH ...

3D rendered Illustration of non-striated Myocytes, non-skeletal, smooth Muscle cells building muscle tissue. Following a prespecified interim analysis, the decision to halt the study was made based on ...

Credit: Shutterstock. The randomized, double-blind, placebo-controlled phase 3 study included 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor.